Core Viewpoint - The company, Basestone Pharmaceuticals, has announced significant advancements in its clinical pipeline, particularly focusing on the dual-targeting antibody CS2011, which shows promise in treating various cancers by effectively blocking key signaling pathways associated with tumor growth [1][22]. Group 1: CS2011 Development - CS2011 is a dual-specific antibody targeting EGFR and HER3, capable of blocking nearly all HER family-related signaling pathways except for HER2 homodimers, thus overcoming tumor heterogeneity [2][5]. - The binding affinity of CS2011 to EGFR is 2.04 nM and to HER3 is 5.04 nM, with a combined affinity of less than 1 pM for both targets [8]. - CS2011 effectively binds to tumor cells expressing either EGFR or HER3 alone, as well as those expressing both [9]. Group 2: Comparative Efficacy - In both in vitro and in vivo studies, CS2011 demonstrated superior anti-tumor activity compared to potential major competitors, including EGFR monoclonal antibodies and HER3 monoclonal antibodies [11][12]. - CS2011's ability to inhibit downstream EGFR signaling is comparable to that of EGFR monoclonal antibodies, while its inhibition of HER3 signaling surpasses that of competing dual-target antibodies [12][14]. - In animal models, CS2011 exhibited tumor suppression effects superior to those of EGFR and HER3 monoclonal antibodies, with efficacy comparable to combination therapies involving both [16]. Group 3: Other Pipeline Products - CS5007, an ADC targeting EGFR and HER3, is designed using the CS2011 antibody framework, aiming to be a leading candidate in precision oncology [21]. - CS5005 is a first-in-class ADC targeting SSTR2, showing strong anti-tumor activity in preclinical studies and good tolerability in initial toxicity studies [22]. - CS5006 is another first-in-class ADC targeting ITGB4, which has shown significant upregulation in various cancers while maintaining low expression in normal tissues, indicating its therapeutic potential [23].
直击AACR 2025|基石药业（02616）公布CS2011（EGFR/HER3双特异性抗体）等多项临床前研究结果